ClinicalTrials.Veeva

Menu

Efficacy of Periorbital Rejuvenation With a 1927 nm Diode Laser Treatment

National Taiwan University logo

National Taiwan University

Status

Completed

Conditions

Periorbital
Laser

Treatments

Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)
Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)

Study type

Interventional

Funder types

Other

Identifiers

NCT05811026
202207219DSC

Details and patient eligibility

About

The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes.

Full description

The chromophore of the 1927 nm diode laser is mainly water, which can be used for skin rejuvenation. This study intends to use the Solta CLEAR+BRILLIANT Laser System, featuring a 1927 nm diode laser with 5 mJ energy, a treatment spot of 140 μm, a treatment depth of 170 μm, and a treatment coverage of approximately 5% per energy level after four rounds of treatment using the patented Intelligent Optical Tracking® System (IOTs). The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes. This is an open-label, single-center clinical trial. Participants will be randomized into treatment groups, including Group A (treatment interval of 2 weeks) or Group B (treatment interval of 4 weeks).

Enrollment

20 patients

Sex

All

Ages

30 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. aged between 30 and 65 years old;
  2. no significant skin lesions or inflammation on the facial skin;
  3. willing and able to comply with study requirements, instructions, and restrictions;
  4. signed informed consent form.

Exclusion criteria

  1. underwent facial active treatment, such as using laser, intense pulsed light, radiofrequency skin tightening, ultrasound skin tightening, botulinum toxin, or dermal fillers injection, within the previous six months;
  2. have chronic skin diseases such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo, rosacea, or keloid;
  3. pregnant or breastfeeding;
  4. suffered from acute illnesses or infections requiring treatment within 14 days before entering the study;
  5. have had serious illnesses (such as heart disease, lung disease, brain disease, or liver disease) within the previous three months;
  6. allergic to Lidocaine or Prilocaine used in topical anesthetic cream or suffer from methemoglobinemia;
  7. used any skin medication on the face within 30 days before the trial, deemed by the principal investigator to affect the study results;
  8. deemed unsuitable for the study by the principal investigator.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

20 participants in 2 patient groups

Arm A: 2-week interval between treatments
Experimental group
Description:
The interval between the first, second, and third treatments in this arm is two weeks, and the follow-up session will take place four weeks after the third treatment.
Treatment:
Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)
Arm B: 4-week interval between treatments
Experimental group
Description:
The interval between the first, second, and third treatments in this arm is four weeks, and the follow-up session will take place four weeks after the third treatment.
Treatment:
Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Chang-Ming Huang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems